Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / ALRN - Aileron begins dosing in phase 1b trial of ALRN-6924 to prevent toxicities due to chemotherapy

ALRN - Aileron begins dosing in phase 1b trial of ALRN-6924 to prevent toxicities due to chemotherapy

Aileron Therapeutics Inc.
Aileron Therapeutics (NASDAQ:ALRN) said it treated the first patients in a phase 1b trial of ALRN-6924 to prevent chemotherapy induced toxicities. The Boston-based company is evaluating ALRN-6924 for preventing chemotherapy-induced neutropenia, other bone marrow toxicities, and toxicities outside of the bone marrow in patients with p53-mutated breast cancer being treated with chemotherapies, doxorubicin plus cyclophosphamide and docetaxel (AC+D). Neutropenia is a condition when the body has fewer neutrophils, type of white blood cells. The company expects initial interim results in Q4 2022.

For further details see:

Aileron begins dosing in phase 1b trial of ALRN-6924 to prevent toxicities due to chemotherapy
Stock Information
Company Name: Aileron Therapeutics Inc.
Stock Symbol: ALRN
Market: NASDAQ
Website: aileronrx.com
Menu
ALRN ALRN Quote ALRN Short ALRN News ALRN Articles ALRN Message Board
Get ALRN Alerts

News, Short Squeeze, Breakout and More Instantly...